Stockscreener 앱 받기
1.91
1.06%
0.02
시간 외 거래:
1.90
-0.01
-0.52%
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX) - GlobeNewswire Inc.
Hay Fever Conjunctivitis Therapeutics Market Size in 7MM - openPR.com
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on - Bluefield Daily Telegraph
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Aldeyra Stockholders and Encourages Investors to Contact the Firm - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response LetterHagens Berman - PR Newswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law - Newsfile
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha
Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA - Contract Pharma
ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations - Newsfile
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
Kirby McInerney LLP Announces Investigation of Possible - GlobeNewswire
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - MSN
Aldeyra Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsADLX - ACCESS Newswire
Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL - insights.citeline.com
Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com India
ALDX ALERT: BFA Law Informs Aldeyra Therapeutics, Inc. Investors to Contact the Firm about its Securities Investigation - Newsfile
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aldeyra vows to go ahead after fresh reproxalap setback - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - markets.businessinsider.com
Jefferies cuts Aldeyra stock target to $6, maintains Buy rating - Investing.com India
Jefferies cuts Aldeyra stock target to $6, maintains Buy rating By Investing.com - Investing.com UK
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA - BioSpace
Levi & Korsinsky Reminds Aldeyra Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsADLX - ACCESS Newswire
H.C. Wainwright maintains Buy on Aldeyra stock, target at $10 - Investing.com India
Aldeyra Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Aldeyra Therapeutics, Inc. (ADLX) - ACCESS Newswire
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health - TipRanks
Aldeyra Therapeutics, Inc. (ADLX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
ADLX STOCK ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - markets.businessinsider.com
Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX - TradingView
Reproxalap rapped again in DED; second Aldeyra CRL - BioWorld MedTech
ADLX ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Aldeyra Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - MSN
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
Top Midday Decliners - MarketScreener
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Sta - Asianet Newsable
US FDA declines to approve Aldeyra's eye disease drug - Reuters
Crude Oil Dips 7%; ISM Services PMI Falls In March - Benzinga
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire
Small cap wrap: Excellon Resources, Trust Stamp, Aldeyra Therapeutics... - Proactive financial news
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud ... - Bluefield Daily Telegraph
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm - GlobeNewswire
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy - Proactive Investors
U.S. FDA declines to approve Aldeyra’s eye disease drug - PharmaLive
US FDA declines to approve Aldeyra’s eye disease drug - The Mighty 790 KFGO
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic - MSN
Aldeyra tumbles as FDA snubs dry eye disease therapy - MSN
4.44%
자본화:
|
볼륨(24시간):